The
first details of how a drug could slow the pace of brain decline for
patients with early stage Alzheimer's disease have emerged.
Data
from pharmaceutical company Eli Lilly suggests its solanezumab drug can
cut the rate of the dementia's progression by about a third.
The results, presented to a US conference, are being met with cautious optimism.
A new trial is due to report next year and should provide definitive evidence.
The death of brain cells in Alzheimer's is currently unstoppable. Solanezumab may be able to keep them alive.
Current medication, such as Aricept, can manage only the symptoms of dementia by helping the dying brain cells function.
